TEMPE, Ariz.--(BUSINESS WIRE)--Sept. 15, 2006--Medistem Laboratories Inc. (OTCBB: MDSM; FWB: S2U), committed to the ethical development and commercialization of medical therapies utilizing adult stem cells, announced today that it has filed an application with the U.S. Patent Office for a patent for “stem cell therapy for cardiac valvular dysfunction.”
